Overview
Munich, April 15, 2025 – With a team led by Holger Ebersberger, McDermott has advised NORD Holding and its portfolio company 1Q Health Group on the acquisition of the German contract research organization VivaCell Biotechnology GmbH.
VivaCell is a privately held, contract research organization (CRO) providing specialized in vitro and ex vivo models for the development and proof of health benefits of cosmetics, oral and body care products, nutraceuticals, food and beverages, pharmaceuticals, probiotics, natural products and botanicals.
1Q Health is a leading European nutritional supplement and pharmaceutical CDMO and development partner. The company produces hard capsules, liquids, powders and tablets under GMP and IFS/FSSC conditions at three production sites in Germany and Austria.
NORD Holding is a private equity and asset management company with assets under management of around EUR 4 billion. With its direct investment division, NORD Holding is currently involved in 13 companies in the DACH region.
McDermott has already advised NORD Holding on several transactions and add-on transactions, including the acquisition of ABJ alive and HKS, which specialize in the contract manufacturing of high-quality nutritional supplements and pharmaceuticals and laid the foundation for the formation of 1Q Health Group.
The McDermott team was led by partner Holger H. Ebersberger and associate Manuel Weiß and comprised counsel Franziska Sauer, partners Christian Rolf and Alexa Ningelen, as well as associates Lene Niemeier and Tim Becker.
